Efficacy of Tegoprazan Based Bismuth Quadruple Therapy for Helicobacter Pylori Infection

• Status: Not yet recruiting
• Trial end date: 2022-03-31
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to investigate eradication rate, drug compliance, and adverse events in patients with confirmed Helicobacter pylori infection between tegoprazan, bismuth, metronidazole, and tetracycline for 14 days (TBMT) and PPI, bismuth, metronidazole, and tetracycline for 14 days (LBMT)

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Incheon St.Mary's Hospital
• Treatments: Dexlansoprazole; Lansoprazole

Criteria

Inclusion Criteria:

patients who male or female aged 19 to 75 years old and fall under the following conditions with confirmed helicobacter pylori infection

Exclusion Criteria:

1. patients who have H.pylori eradication history

2. patients with history of gastric cancer surgery

3. patients who have taken antibiotics within 4 weeks prior to trial

4. a person who taking HIV protease inhibitors (atazanavir, nelfinavir) or a drug containing rilpivirine

5. pregnant or breastfeeding women